NeuroOne Medical Technologies (NASDAQ:NMTC) Issues Earnings Results

12 May 2026, 13:40 by Scott Moore · The Cerbat Gem

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), FiscalAI reports. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.The company had revenue of $2.39 million for the quarter, compared to the consensus estimate of $2.58 million.

Here are the key takeaways from NeuroOne Medical Technologies’ conference call:

NeuroOne reported 72% year-over-year product revenue growth in Q2 fiscal 2026 to $2.4 million, driven by higher sales of its OneRF products.
Management highlighted continued clinical traction for the OneRF Trigeminal Nerve Ablation System, with 16 cases completed and all patients reportedly pain-free after the procedure.
The company said it completed the stage 2 ISO 13485 audit of its Minnesota facility and remains optimistic about certification in late 2026, which would support international distribution.
NeuroOne reaffirmed its full-year product revenue guidance of $10.5 million, noting it does not yet include meaningful contributions from drug delivery or facial pain commercialization.
The company ended the quarter with $2.8 million in cash and no debt, while also announcing a CFO transition in which Ron McClurg will retire and Chris Volker will take over effective July 1, 2026.

NeuroOne Medical Technologies Stock Up 2.2%

Shares of NMTC traded up $0.10 during midday trading on Tuesday, reaching $4.43. 21,763 shares of the stock were exchanged, compared to its average volume of 43,405. NeuroOne Medical Technologies has a twelve month low of $3.27 and a twelve month high of $6.96. The company has a market cap of $37.26 million, a P/E ratio of -4.34 and a beta of 0.60. The stock’s 50 day simple moving average is $4.55 and its 200 day simple moving average is $4.56.

Insider Activity

In related news, insider David J. Wambeke purchased 166,666 shares of the business’s stock in a transaction that occurred on Sunday, March 1st. The stock was acquired at an average cost of $4.02 per share, for a total transaction of $669,997.32. Following the completion of the purchase, the insider owned 166,666 shares in the company, valued at approximately $669,997.32. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 2,438 shares of company stock valued at $11,702 in the last three months. Insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

Several large investors have recently modified their holdings of NMTC. XTX Topco Ltd increased its position in shares of NeuroOne Medical Technologies by 321.1% in the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock worth $65,000 after purchasing an additional 65,163 shares during the period. Squarepoint Ops LLC acquired a new stake in NeuroOne Medical Technologies during the fourth quarter worth about $36,000. Essex Investment Management Co. LLC bought a new position in NeuroOne Medical Technologies in the 4th quarter valued at about $143,000. Renaissance Technologies LLC increased its holdings in NeuroOne Medical Technologies by 10.2% in the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock valued at $578,000 after buying an additional 70,428 shares during the period. Finally, Susquehanna International Group LLP bought a new position in NeuroOne Medical Technologies in the 3rd quarter valued at about $47,000. 16.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NMTC has been the subject of a number of research analyst reports. JonesTrading initiated coverage on shares of NeuroOne Medical Technologies in a research report on Monday, March 2nd. They set a “buy” rating and a $9.00 price objective for the company. Zacks Research cut shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th. Finally, Wall Street Zen raised shares of NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $13.50.

View Our Latest Research Report on NMTC

About NeuroOne Medical Technologies

(Get Free Report)

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.